市场调查报告书
商品编码
1390691
血友病市场:2023-2028 年全球产业趋势、份额、规模、成长、机会与预测Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年全球血友病市场规模达117亿美元。展望未来, IMARC Group预计到2028年市场规模将达到223亿美元,2022-2028年复合年增长率(CAGR)为11.35%。
血友病是一种影响血液凝固过程的遗传性医学疾病,其中血液凝固异常。它会导致受伤、手术和牙科手术后自发性出血和过度出血、容易瘀伤和渗血。它是由遗传性缺乏凝血因子引起的,由于缺乏足够的凝血蛋白,凝血因子会减慢血液凝固。可以使用药物、替代疗法和注射凝血因子或血浆来治疗。其治疗重点是替换缺失的蛋白质和预防併发症。
全球血友病患者数量的增加和个体遗传异常发生率的增加是积极影响市场的关键因素之一。此外,疾病诊断率的上升以及血友病预防性治疗的日益普及,为领先的市场参与者提供了利润丰厚的成长机会。除此之外,各国管理机构正在组织大量活动,以宣传早期诊断的好处,并遵循适当的程序来促进新生儿的早期筛检,这为市场创造了积极的前景。此外,由于治疗方案的可用性有限,他们越来越多地资助研究和开发 (R&D) 活动。此外,领先的产业参与者正致力于引进技术先进的诊断工具和疗法,以提高血友病治疗的功效和准确性,这提供了良好的市场前景。此外,预计在全球范围内扩大建立专门的血友病治疗中心(HTC)的大量投资将推动市场的发展。
The global hemophilia market size reached US$ 11.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.35% during 2022-2028.
Hemophilia is an inherited medical disorder that affects the blood clotting process, wherein the blood clots abnormally. It results in spontaneous and excessive bleeding, easy bruising, and oozing after an injury, surgery, and dental procedures. It is caused by a hereditary lack of a coagulation factor that slows down blood clotting due to the deficiency of adequate blood-clotting proteins. It can be treated using medications, replacement therapy and injections of a clotting factor or plasma. Its treatment focuses on replacing missing proteins and preventing complications.
The increasing number of hemophilic patients and rising occurrences of genetic abnormalities among individuals across the globe represents one of the key factors positively influencing the market. In addition, the rising diagnosis rate of the illness and the growing popularity of prophylactic treatment to cure hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, governing agencies of various countries are organizing numerous campaigns to spread awareness about the benefits of early diagnosis and following appropriate procedures to facilitate the early screening of neonates, which is creating a positive outlook for the market. Additionally, they are increasingly funding research and development (R&D) activities due to the limited availability of treatment options. Furthermore, leading industry players are focusing on introducing technologically advanced diagnostic tools and therapies to enhance the efficacy and accuracy of hemophilia treatment, which is offering a favorable market outlook. Moreover, extensive investments in expanding the establishment of specialized hemophilia treatment centers (HTCs) across the globe are anticipated to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemophilia market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment and therapy.
Hemophilia A
Hemophilia B
Hemophilia C
Others
Hemophilia A represents the largest market segment due to the rising prevalence of hemophilia A among individuals across the globe and the increasing requirement for patient care.
On-Demand
Prophylaxis
On-demand treatment currently holds the largest market share as it is highly beneficial for patients with mild or moderate hemophilia who bleed less often.
Replacement Therapy
ITI Therapy
Gene Therapy
Replacement therapy is a standard therapy used to treat hemophilia as it helps replace the missing clotting factor among patients. It involves offering the missing clotting factor to patients from an external source.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market due to the increasing government spending on healthcare and research and development (R&D) activities, along with the presence of various leading players in the country.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.